294 related articles for article (PubMed ID: 34602041)
21. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Przybyłowska M; Dzierzbicka K; Kowalski S; Chmielewska K; Inkielewicz-Stepniak I
Curr Neuropharmacol; 2021; 19(8):1323-1344. PubMed ID: 33342413
[TBL] [Abstract][Full Text] [Related]
22. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and molecular docking studies of 5-trifluoromethoxy-2-indolinones as cholinesterase dual inhibitors.
Soylu-Eter Ö; Özsoy N; Karalı N
Future Med Chem; 2024 Apr; 16(7):623-645. PubMed ID: 38470247
[No Abstract] [Full Text] [Related]
25. Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs.
Mohamed LW; Mohamed KO; Sayed HS; Mahmoud Z
Med Chem; 2023; 19(4):311-324. PubMed ID: 36043761
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
27. Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Zhou Y; He Y; Teng X; Mi J; Yang J; Wei R; Liu W; Ma Q; Tan Z; Sang Z
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2231661. PubMed ID: 37414563
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G; Buccioni M; Ben DD; Lambertucci C; Volpini R; Amenta F
Neuropharmacology; 2021 Jun; 190():108352. PubMed ID: 33035532
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Zurek E; Szymański P; Mikiciuk-Olasik E
Drug Res (Stuttg); 2013 Mar; 63(3):137-44. PubMed ID: 23447117
[TBL] [Abstract][Full Text] [Related]
30. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
32. Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Kaushik V; Smith ST; Mikobi E; Raji MA
Am J Alzheimers Dis Other Demen; 2018 Mar; 33(2):73-85. PubMed ID: 28974110
[TBL] [Abstract][Full Text] [Related]
33. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
Pathak C; Kabra UD
Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
[TBL] [Abstract][Full Text] [Related]
35. A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer's Disease Treatment.
Kalari M; Abbasi Z; Shasaltaneh MD; Khaleghian A; Moosavi-Nejad Z
J Alzheimers Dis; 2022; 87(4):1503-1516. PubMed ID: 35527546
[TBL] [Abstract][Full Text] [Related]
36. Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina.
Bezerra da Silva C; Pott A; Elifio-Esposito S; Dalarmi L; Fialho do Nascimento K; Moura Burci L; de Oliveira M; de Fátima Gaspari Dias J; Warumby Zanin SM; Gomes Miguel O; Dallarmi Miguel M
Molecules; 2016 Jan; 21(1):53. PubMed ID: 26760993
[TBL] [Abstract][Full Text] [Related]
37. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
Singh YP; Kumar N; Chauhan BS; Garg P
Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
[TBL] [Abstract][Full Text] [Related]
38. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels.
Li XT
Metab Brain Dis; 2022 Mar; 37(3):581-587. PubMed ID: 35098414
[TBL] [Abstract][Full Text] [Related]
40. Acetylcholinesterase inhibitors: novel activities of old molecules.
Racchi M; Mazzucchelli M; Porrello E; Lanni C; Govoni S
Pharmacol Res; 2004 Oct; 50(4):441-51. PubMed ID: 15304241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
